Demand Drives Goodwin Biotech to Double Contract Manufacturing Capacity in Florida

---

Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas). Following an ongoing trend within the Pharma-Biotech Industry (reference: 2007 Pharmaceutical-Biotech Industry Forecast), Goodwin Biotechnology Incorporated (Plantation, Florida) is wrapping up construction on an expansion project that will double its cGMP capacity. The contract manufacturer (CMO) produces monoclonal antibodies and recombinant proteins for preclinical and Phase I/II/III clinical trials.

The expansion, which began last year (Source: Pharmaceutical Tracker) includes the addition of two new manufacturing suites featuring ABEC stir tank bioreactors (250 and 500 liters). There is room for further expansion as need dictates. In addition to being relocated, the 28,000 square-foot site’s process development laboratory was also expanded and upgraded.

The new manufacturing suites will be initially outfitted with two ABEC bioreactors, sized at 200 Liters and 500 Liters. Late summer of 2007 is the scheduled completion of the expansion project, including installation of the bioreactors. Spun out of the Goodwin Institute for Cancer Research in 1992, Goodwin first began manufacturing Phase III products in 2005, when it secured a contract from the Menarini Group, based in Italy, to manufacture its Phase III ovarian cancer antibody. In late 2004, the company was acquired by Wallace USA, a division of Wallace Pharmaceuticals Limited, a solid dose formulation manufacturer located in Goa, India.

View Project Report - 05002369

Industrial Info Resources (IIR) provides marketing communication services ranging from industrial database solutions to market forecasting, custom analytics, and specialty promotions that support high-level image campaigns.